Immunoreconstitution in children receiving highly active antiretroviral therapy depends on the CD4 cell percentage at baseline
- PMID: 11807710
- DOI: 10.1086/338567
Immunoreconstitution in children receiving highly active antiretroviral therapy depends on the CD4 cell percentage at baseline
Abstract
The effect of highly active antiretroviral therapy (HAART) in 85 children infected with human immunodeficiency virus type 1 (HIV-1) was compared retrospectively among Centers for Disease Control and Prevention (CDC) immunologic groups 1-3. The duration of HAART did not vary significantly among the immunologic groups (median, 39.07 months). The CD4 cell percentage increased in 39.1%, 58.3%, and 90% of patients in CDC groups 1-3, respectively (P <.001). HAART resulted in the suppression of HIV-1 below detectable levels in 34.8%, 25%, and 32% of patients in the 3 CDC groups, respectively, and in a frequent switch from syncytium-inducing to nonsyncytium-inducing virus. Thymic excision circles increased in a subset of patients with increases in CD4 cell percentage independently of HIV RNA level. The results support the option of delaying HAART in early asymptomatic HIV-1 disease in children and the use of other markers of disease progression, in addition to virus load.
Similar articles
-
Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.Clin Infect Dis. 2004 Sep 1;39(5):725-31. doi: 10.1086/423178. Epub 2004 Aug 16. Clin Infect Dis. 2004. PMID: 15356789
-
Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.Clin Infect Dis. 2006 Mar 15;42(6):862-9. doi: 10.1086/500412. Epub 2006 Feb 9. Clin Infect Dis. 2006. PMID: 16477566
-
CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.Clin Infect Dis. 2007 Feb 1;44(3):441-6. doi: 10.1086/510746. Epub 2006 Dec 20. Clin Infect Dis. 2007. PMID: 17205456
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
Virologic and immunologic response to highly active antiretroviral therapy.Curr HIV/AIDS Rep. 2004 Jun;1(2):74-81. doi: 10.1007/s11904-004-0011-1. Curr HIV/AIDS Rep. 2004. PMID: 16091226 Review.
Cited by
-
Quantification of CD4 responses to combined antiretroviral therapy over 5 years among HIV-infected children in Kinshasa, Democratic Republic of Congo.J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):90-8. doi: 10.1097/QAI.0b013e31825bd9b7. J Acquir Immune Defic Syndr. 2012. PMID: 22732464 Free PMC article.
-
Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescents.AIDS. 2015 Mar 27;29(6):683-93. doi: 10.1097/QAD.0000000000000598. AIDS. 2015. PMID: 25849832 Free PMC article.
-
Recent Thymus Emigrant CD4+ T Cells Predict HIV Disease Progression in Patients With Perinatally Acquired HIV.Clin Infect Dis. 2016 Apr 15;62(8):1029-1035. doi: 10.1093/cid/ciw030. Epub 2016 Feb 21. Clin Infect Dis. 2016. PMID: 26908808 Free PMC article.
-
Impaired immunity to recall antigens and neoantigens in severely immunocompromised children and adolescents during the first year of effective highly active antiretroviral therapy.J Infect Dis. 2008 Oct 15;198(8):1123-30. doi: 10.1086/592050. J Infect Dis. 2008. PMID: 18752430 Free PMC article. Clinical Trial.
-
Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting.Clin Infect Dis. 2008 Jun 1;46(11):1751-60. doi: 10.1086/587900. Clin Infect Dis. 2008. PMID: 18426371 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials